This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Homology Medicines (FIXX) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Homology Medicines (FIXX) delivered earnings and revenue surprises of 9.09% and 40.59%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Invitae (NVTA) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Invitae (NVTA) delivered earnings and revenue surprises of 9.76% and 1.87%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
CareCloud, Inc. (CCLD) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
CareCloud, Inc. (CCLD) delivered earnings and revenue surprises of 9.68% and 3.14%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Inspire Medical Systems (INSP) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Inspire (INSP) delivered earnings and revenue surprises of 24.29% and 6.07%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Phreesia (PHR) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Phreesia (PHR) delivered earnings and revenue surprises of 7.69% and 2.56%, respectively, for the quarter ended January 2023. Do the numbers hold clues to what lies ahead for the stock?
Sonendo, Inc. (SONX) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Sonendo, Inc. (SONX) delivered earnings and revenue surprises of 45.45% and 5.13%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Cooper Companies (COO) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
Cooper Companies' (COO) fiscal first-quarter results are likely to reflect segmental strength.
What's in Store for Patterson Companies (PDCO) in Q3 Earnings?
by Zacks Equity Research
Patterson Companies' (PDCO) fiscal third-quarter results are likely to reflect an improvement at the Animal Health segment.
What Makes Phreesia (PHR) a New Buy Stock
by Zacks Equity Research
Phreesia (PHR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Phreesia (PHR) Soars 6.1%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Phreesia (PHR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Phreesia (PHR) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Phreesia (PHR) delivered earnings and revenue surprises of 13.64% and 2.73%, respectively, for the quarter ended October 2022. Do the numbers hold clues to what lies ahead for the stock?
MEI Pharma, Inc. (MEIP) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
MEI Pharma, Inc. (MEIP) delivered earnings and revenue surprises of 0% and 10.46%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Neovasc (NVCN) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Neovasc (NVCN) delivered earnings and revenue surprises of -6.38% and 7.70%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Cue Health Inc. (HLTH) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cue Health Inc. (HLTH) delivered earnings and revenue surprises of 21.82% and 19.92%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Can Phreesia (PHR) Climb 26% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 25.7% in Phreesia (PHR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Phreesia (PHR) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Phreesia (PHR) delivered earnings and revenue surprises of 10.10% and 3.04%, respectively, for the quarter ended July 2022. Do the numbers hold clues to what lies ahead for the stock?
Nemaura Medical, Inc. (NMRD) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Nemaura Medical, Inc. (NMRD) delivered earnings and revenue surprises of -6.25% and 100%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Olink Holding AB publ Sponsored ADR (OLK) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Olink Holding AB publ Sponsored ADR (OLK) delivered earnings and revenue surprises of 69.23% and 3.75%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
SOPHiA GENETICS SA (SOPH) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
SOPHiA GENETICS SA (SOPH) delivered earnings and revenue surprises of 0% and 0.88%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Wall Street Analysts See a 38% Upside in Phreesia (PHR): Can the Stock Really Move This High?
by Zacks Equity Research
The mean of analysts' price targets for Phreesia (PHR) points to a 37.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Here's Why Phreesia (PHR) Is a Great 'Buy the Bottom' Stock Now
by Zacks Equity Research
After losing some value lately, a hammer chart pattern has been formed for Phreesia (PHR), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Wall Street Analysts Think Phreesia (PHR) Could Surge 26%: Read This Before Placing a Bet
by Zacks Equity Research
The consensus price target hints at a 25.5% upside potential for Phreesia (PHR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Phreesia (PHR) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Phreesia (PHR) delivered earnings and revenue surprises of 9.17% and 1.49%, respectively, for the quarter ended April 2022. Do the numbers hold clues to what lies ahead for the stock?
Phreesia (PHR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Phreesia (PHR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Nextgen Healthcare (NXGN) Q4 Earnings Miss Estimates
by Zacks Equity Research
Nextgen Healthcare (NXGN) delivered earnings and revenue surprises of -5% and 0.24%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?